Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single topical dose safety and pharmacokinetics study of M605110 in acne vulgaris
jRCT2031220537Phase 1Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acne vulgaris comparing M605110 5% single topical dose with M605110 placebo single topical dose (2 arms). Primary endpoints: Safety (systemic and local) and Pharmacokinetics of benzoyl peroxide exposure. Started Feb 2023; status: completed.
02
Drugs
M605110
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on jRCT2031220537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220537.